188 related articles for article (PubMed ID: 35332789)
1. Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model.
Hinahara J; Weinzimer SA; Bromley ER; Goss TF; Kendall DM; Hammer M
J Manag Care Spec Pharm; 2022 Apr; 28(4):461-472. PubMed ID: 35332789
[No Abstract] [Full Text] [Related]
2. A ready-to-use liquid glucagon for treatment of severe hypoglycemia demonstrates reduced healthcare payer costs in a budget impact model.
Leinwand B; Johnsrud M; Nguyen A; Meyer J; Johnson K
J Med Econ; 2020 Jul; 23(7):744-750. PubMed ID: 32162983
[No Abstract] [Full Text] [Related]
3. A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe Hypoglycemia.
Bailey NC; Dimsits J; Hammer M; Kendall DM; Bailey TS
Diabetes Technol Ther; 2022 Apr; 24(4):231-240. PubMed ID: 34809479
[No Abstract] [Full Text] [Related]
4. Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.
Pöhlmann J; Mitchell BD; Bajpai S; Osumili B; Valentine WJ
J Diabetes Sci Technol; 2019 Sep; 13(5):910-918. PubMed ID: 30700165
[TBL] [Abstract][Full Text] [Related]
5. Dasiglucagon: an effective medicine for severe hypoglycemia.
Xu B; Tang G; Chen Z
Eur J Clin Pharmacol; 2021 Dec; 77(12):1783-1790. PubMed ID: 34223944
[TBL] [Abstract][Full Text] [Related]
6. Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.
Pieber TR; Aronson R; Hövelmann U; Willard J; Plum-Mörschel L; Knudsen KM; Bandak B; Tehranchi R
Diabetes Care; 2021 Jun; 44(6):1361-1367. PubMed ID: 35239971
[TBL] [Abstract][Full Text] [Related]
7. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.
Battelino T; Tehranchi R; Bailey T; Dovc K; Melgaard A; Yager Stone J; Woerner S; von dem Berge T; DiMeglio L; Danne T
Pediatr Diabetes; 2021 Aug; 22(5):734-741. PubMed ID: 33934456
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
Hövelmann U; Bysted BV; Mouritzen U; Macchi F; Lamers D; Kronshage B; Møller DV; Heise T
Diabetes Care; 2018 Mar; 41(3):531-537. PubMed ID: 29273578
[TBL] [Abstract][Full Text] [Related]
9. Dasiglucagon: A Novel Ready-to-Use Treatment for Severe Hypoglycemia.
Goodhart AL
Ann Pharmacother; 2023 Mar; 57(3):300-305. PubMed ID: 35861467
[TBL] [Abstract][Full Text] [Related]
10. Dasiglucagon: First Approval.
Blair HA
Drugs; 2021 Jun; 81(9):1115-1120. PubMed ID: 34047955
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modeling analysis.
Yale JF; Osumili B; Mitchell BD; Hunt B; Sohi G; Jeddi M; Mojdami D; Valentine WJ
J Med Econ; 2022; 25(1):238-248. PubMed ID: 35094622
[TBL] [Abstract][Full Text] [Related]
12. Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes.
Heller S; Battelino T; Bailey TS; Pieber TR; Hövelmann U; Plum-Mörschel L; Melgaard AE; Aronson R; DiMeglio LA; Johansen T; Danne T
Diabetes Obes Metab; 2023 May; 25(5):1351-1360. PubMed ID: 36692230
[TBL] [Abstract][Full Text] [Related]
13. Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial.
Bailey TS; Willard J; Klaff LJ; Yager Stone J; Melgaard A; Tehranchi R
Diabetes Obes Metab; 2021 Oct; 23(10):2329-2335. PubMed ID: 34169625
[TBL] [Abstract][Full Text] [Related]
14. Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain.
Osumili B; Artime E; Mitchell B; Rubio-de Santos M; Díaz-Cerezo S; Giménez M; Spaepen E; Sharland H; Valentine WJ
Diabetes Ther; 2022 Apr; 13(4):775-794. PubMed ID: 35297026
[TBL] [Abstract][Full Text] [Related]
15. Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes.
Li S; Hu Y; Tan X; Wang D; Hu J; Zou P; Wang L
Expert Opin Pharmacother; 2020 Aug; 21(11):1311-1318. PubMed ID: 32267182
[TBL] [Abstract][Full Text] [Related]
16. Dasiglucagon for the Treatment of Insulin-induced Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Meta-analysis.
Maji S; Mohanty RR; Maiti R
Balkan Med J; 2023 Oct; 40(6):400-408. PubMed ID: 37735694
[TBL] [Abstract][Full Text] [Related]
17. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
[No Abstract] [Full Text] [Related]
18. Dasiglucagon for treating severe hypoglycemia in patients with diabetes.
Ju Y; Zhang D; Yang J
Expert Rev Clin Pharmacol; 2022 Jul; 15(7):799-803. PubMed ID: 35848442
[TBL] [Abstract][Full Text] [Related]
19. New Fast Acting Glucagon for Recovery from Hypoglycemia, a Life-Threatening Situation: Nasal Powder and Injected Stable Solutions.
La Sala L; Pontiroli AE
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638984
[TBL] [Abstract][Full Text] [Related]
20. NASAL GLUCAGON DELIVERY IS MORE SUCCESSFUL THAN INJECTABLE DELIVERY: A SIMULATED SEVERE HYPOGLYCEMIA RESCUE.
Settles JA; Gerety GF; Spaepen E; Suico JG; Child CJ
Endocr Pract; 2020 Apr; 26(4):407-415. PubMed ID: 32293921
[No Abstract] [Full Text] [Related]
[Next] [New Search]
